Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068873 · ClinicalTrials.gov registry record · Phase 4
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
A Phase 4 study, sponsored by Temple University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01068873 is a Phase 4 study that was terminated before completion, run by Temple University. The registered enrollment target is 1 participants.
The verdict
NCT01068873, a Phase 4 study, was terminated before completion, sponsored by Temple University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled and studied for 48 weeks.
Interventions
- DRUG lopinavir/ritonavir plus maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068873
The ClinicalTrials.gov registry entry for NCT01068873 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lopinavir/ritonavir plus maraviroc is the first listed.
NCT01068873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01068873 about?
NCT01068873 is a clinical study titled "Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)". The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled...
What is the current status of trial NCT01068873?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01068873?
The interventions under investigation include: lopinavir/ritonavir plus maraviroc (DRUG).
Who is sponsoring clinical trial NCT01068873?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.